Insider · CIK 0001881190

Gheuens Sarah

Reports to the SEC for 2 companies · CAMBRIDGE, MA

sec.gov

Transactions

Companies

Filings

CIK

0001881190

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-10-22	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−500 sh	—	—	24,141
2026-10-22	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−500 sh	$37.52	−$18.8K	54,645
2026-10-22	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+500 sh	$25.01	+$12.5K	55,145
2026-10-21	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−1,489 sh	—	—	24,641
2026-10-21	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−1,489 sh	$37.53	−$55.9K	54,645
2026-10-21	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+1,489 sh	$25.01	+$37.2K	56,134
2026-08-04	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−30K sh	$30.48	−$914K	54,645
2026-07-01	VRDNViridian Therapeutics, Inc.\DE · Stock Option (Right to Buy)A Award	Director	AAward	+32.3K sh	—	—	32,341
2026-07-01	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+8,375 sh	—	—	88,652
2026-07-01	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−4,007 sh	$37.56	−$151K	84,645
2026-07-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−8,375 sh	—	—	0
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−3,000 sh	—	—	9,000
2026-06-18	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Medical Officer	AAward	+3,000 sh	—	—	3,000
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+8,500 sh	—	—	83,217
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−2,940 sh	$34.71	−$102K	80,277
2026-04-02	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−8,500 sh	—	—	8,500
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+4,000 sh	—	—	68,795
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−1,187 sh	$28.96	−$34.4K	67,608
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+5,666 sh	—	—	73,274
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−1,681 sh	$28.96	−$48.7K	71,593
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+4,000 sh	—	—	75,593
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−1,187 sh	$28.96	−$34.4K	74,406
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−4,000 sh	—	—	0
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−5,666 sh	—	—	5,667
2026-03-02	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−4,000 sh	—	—	8,000
2026-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Medical Officer	AAward	+14K sh	—	—	14,000
2026-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsA Award	Chief Medical Officer	AAward	+22K sh	—	—	22,000
2026-03-01	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)A Award	Chief Medical Officer	AAward	+52K sh	—	—	52,000
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+6,000 sh	—	—	67,727
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−2,932 sh	$27.09	−$79.4K	64,795
2025-12-30	AGIOAGIOS PHARMACEUTICALS, INC. · Performance share unitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−6,000 sh	—	—	0
2025-11-11	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+2,454 sh	$25.01	+$61.4K	64,181
2025-11-11	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−2,454 sh	$43.78	−$107K	61,727
2025-11-11	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−2,454 sh	—	—	26,130
2025-10-30	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+200 sh	$25.01	+$5,002	61,927
2025-10-30	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−200 sh	$43.81	−$8,762	61,727
2025-10-30	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−200 sh	—	—	28,584
2025-10-27	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+3,302 sh	$25.01	+$82.6K	65,029
2025-10-27	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−3,302 sh	$43.92	−$145K	61,727
2025-10-27	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−3,302 sh	—	—	28,784
2025-07-09	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+11.9K sh	$25.01	+$298K	73,185
2025-07-09	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−11.1K sh	$37.93	−$420K	62,118
2025-07-09	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−847 sh	$38.76	−$32.8K	61,271
2025-07-09	AGIOAGIOS PHARMACEUTICALS, INC. · Stock options (right to buy)M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−11.9K sh	—	—	32,086
2025-07-01	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+8,374 sh	—	—	65,362
2025-07-01	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−4,091 sh	$34.17	−$140K	61,271
2025-07-01	AGIOAGIOS PHARMACEUTICALS, INC. · Restricted stock unitsM Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	−8,374 sh	—	—	8,375
2025-07-01	VRDNViridian Therapeutics, Inc.\DE · Stock Option (Right to Buy)A Award	Director	AAward	+21K sh	—	—	21,000
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC.M Exercise/Conversion	Chief Medical Officer	MExercise/Conversion	+6,000 sh	—	—	59,897
2025-06-24	AGIOAGIOS PHARMACEUTICALS, INC.S Sale	Chief Medical Officer	SSale	−2,909 sh	$33.54	−$97.6K	56,988

Recent filings

Accepted (ET)
Oct 234
Gheuens Sarah0001439222-26-000122
SEC(opens sec.gov)
Aug 64
Gheuens Sarah0001439222-26-000120
SEC(opens sec.gov)
Jul 24
Gheuens Sarah0001439222-26-000110
SEC(opens sec.gov)
Jul 24
Gheuens Sarah0001193125-26-294552
SEC(opens sec.gov)
Jun 234
Gheuens Sarah0001439222-26-000085
SEC(opens sec.gov)
Apr 64
Gheuens Sarah0001439222-26-000065
SEC(opens sec.gov)
Mar 34
Gheuens Sarah0001439222-26-000040
SEC(opens sec.gov)

Companies

Address

88 SIDNEY STREET

CAMBRIDGE, MA, 02139